EFLORNITHINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Uswm	IWILFIN	eflornithine hydrochloride	TABLET;ORAL	215500	NDA	USWM, LLC	78670-150-01	1 BOTTLE in 1 CARTON (78670-150-01) / 100 TABLET in 1 BOTTLE	2024-01-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Eflornithine hydrochloride, an ornithine decarboxylase inhibitor, is a critical active pharmaceutical ingredient (API) for treating African trypanosomiasis (sleeping sickness) and hirsutism. The global supply chain for eflornithine hydrochloride API is concentrated among a limited number of manufacturers, posing potential risks and requiring careful supplier qualification and diversification strategies. Key suppliers are located in India and China, with a few additional producers in Europe.

KEY API MANUFACTURERS AND PRODUCTION CAPACITIES

The production of eflornithine hydrochloride API is primarily controlled by a select group of manufacturers. These entities possess the necessary regulatory approvals, manufacturing infrastructure, and quality control systems to produce API meeting stringent pharmacopoeial standards.

India-based Manufacturers:
- IPCA Laboratories Ltd.: A major Indian pharmaceutical company with a significant API manufacturing presence. IPCA is a well-established supplier of eflornithine hydrochloride, holding numerous regulatory filings in various markets. Their production capacity is estimated to be substantial, supporting both global tenders and commercial markets. [1]
- Divi’s Laboratories Limited: Another prominent Indian API manufacturer known for its high-volume production capabilities across a range of therapeutic areas. Divi's is recognized for its integrated manufacturing processes and robust quality management systems. [2]
- Laurus Labs Limited: While also a significant player in other API segments, Laurus Labs has capabilities that could extend to complex molecules like eflornithine hydrochloride. Their focus on process innovation and cost-effective manufacturing is a key differentiator. [3]
China-based Manufacturers:
- Hubei Biocause Pharmaceutical Co., Ltd.: A substantial Chinese pharmaceutical enterprise with a broad portfolio of APIs. Hubei Biocause is a known producer of eflornithine hydrochloride and plays a role in the global supply. [4]
- AnkeBio Co., Ltd.: This company is also identified as a supplier of eflornithine hydrochloride API, contributing to the capacity available from China.
European Manufacturers:
- Chephapharma GmbH & Co. KG: A German pharmaceutical company specializing in the development and manufacturing of APIs. Chephapharma offers contract manufacturing services and has the potential to produce eflornithine hydrochloride. Their European base offers an alternative geographic sourcing option. [5]

Production capacities for eflornithine hydrochloride API are not publicly disclosed by manufacturers. However, based on their market presence and established operations, IPCA Laboratories and Divi’s Laboratories are presumed to have the largest individual capacities. The total global annual production capacity is difficult to quantify precisely due to proprietary information but is understood to be sufficient to meet current global demand, particularly for humanitarian programs like the World Health Organization's (WHO) sleeping sickness treatment initiative. [6]

REGULATORY LANDSCAPE AND QUALITY STANDARDS

Eflornithine hydrochloride API must adhere to rigorous quality standards and regulatory requirements to ensure patient safety and therapeutic efficacy. Key regulatory bodies and pharmacopoeias dictate these standards.

United States Pharmacopeia (USP): The USP monograph for Eflornithine Hydrochloride establishes specifications for identity, purity, assay, and other critical quality attributes. Manufacturers must comply with these standards for API intended for the U.S. market. [7]
European Pharmacopoeia (Ph. Eur.): Similar to the USP, the Ph. Eur. provides detailed requirements for eflornithine hydrochloride. Compliance with Ph. Eur. is essential for API entering the European market. [8]
International Conference on Harmonisation (ICH): ICH guidelines, particularly those pertaining to Good Manufacturing Practices (GMP), are globally recognized and adopted. Manufacturers must demonstrate adherence to ICH Q7 for API manufacturing. [9]
World Health Organization (WHO): For treatments of neglected tropical diseases like African trypanosomiasis, the WHO prequalifies APIs and finished products. Prequalification ensures that a medicine meets international quality standards and is safe and effective. Manufacturers supplying to WHO-administered programs must undergo rigorous WHO prequalification assessments. [10]

The primary manufacturing sites for eflornithine hydrochloride API are subject to inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities. Successful completion of these inspections and maintenance of current GMP compliance are prerequisites for market access.

SUPPLY CHAIN CHALLENGES AND RISK MITIGATION

The consolidated nature of eflornithine hydrochloride API manufacturing presents inherent supply chain risks that require proactive management by pharmaceutical companies and procurement organizations.

Single-Sourcing Dependency: Reliance on a limited number of suppliers can create vulnerabilities. Disruptions at a single manufacturing site due to quality issues, regulatory actions, or geopolitical events can have immediate and severe consequences for drug availability.
Geopolitical Instability: A significant portion of global eflornithine hydrochloride API production is concentrated in India and China. Changes in trade policies, import/export restrictions, or political instability in these regions can impact supply.
Lead Times and Production Planning: The specialized nature of API synthesis means that production schedules are often planned well in advance. Long lead times can make it challenging to respond quickly to unexpected demand surges or supply interruptions.
Quality Control and Batch Variability: Maintaining consistent quality across batches and suppliers is paramount. Any deviation from established specifications can lead to batch rejection, impacting inventory and downstream production.
Cost Volatility: Raw material costs, energy prices, and labor expenses can fluctuate, impacting the overall cost of API production. Manufacturers may pass these increases onto buyers, affecting drug pricing.

Risk Mitigation Strategies:

Supplier Diversification: Identifying and qualifying secondary and tertiary suppliers is crucial. This involves rigorous due diligence, technical transfer, and establishing quality agreements with multiple API manufacturers.
Robust Quality Agreements: Comprehensive quality agreements with API suppliers should define responsibilities, change control procedures, deviation management, and audit rights.
Inventory Management: Maintaining adequate safety stock of API and finished drug product can buffer against short-term supply disruptions. This requires careful forecasting and inventory planning.
Geographic Diversification: Where feasible, sourcing API from manufacturers located in different geographic regions can reduce exposure to localized risks.
Strategic Partnerships: For critical APIs like eflornithine hydrochloride, forging long-term strategic partnerships with key suppliers can improve supply chain reliability and visibility. This can involve joint forecasting, capacity planning, and collaborative quality improvement initiatives.
Regulatory Intelligence: Proactively monitoring regulatory changes and inspection trends in key manufacturing regions allows for early identification of potential compliance issues.

PRICING AND TENDER DYNAMICS

The pricing of eflornithine hydrochloride API is influenced by several factors, including manufacturing costs, regulatory compliance expenses, market demand, and the dynamics of procurement processes, particularly for large-scale humanitarian programs.

Cost of Goods Sold (COGS): This includes raw materials, solvents, energy, labor, and depreciation of manufacturing assets. The synthesis of eflornithine hydrochloride involves multiple chemical steps, contributing to its cost.
Regulatory Compliance Costs: The investment in GMP-compliant facilities, quality control laboratories, and personnel for regulatory filings and ongoing compliance adds to the API cost.
Market Demand: Demand for eflornithine hydrochloride is bifurcated. A significant portion is driven by the need for treating sleeping sickness, often procured through global health organizations. The other segment is for the cosmetic treatment of hirsutism, primarily through topical formulations.
Tender-Based Procurement: For sleeping sickness treatment, procurement is often conducted through tenders organized by the WHO or other international bodies. These tenders aim to secure large volumes of API and finished product at competitive prices. Manufacturers bid based on their production costs, quality, and reliability. [6]
Spot Market vs. Long-Term Contracts: Pricing can vary significantly between spot market purchases and long-term supply agreements. Long-term contracts typically offer more stable pricing but may involve commitments to specific volumes.

Precise pricing benchmarks for eflornithine hydrochloride API are not publicly available and can vary based on volume, grade, supplier, and the specific procurement mechanism. However, it is understood that prices for API supplied to humanitarian programs are significantly lower than those for the commercial cosmetic market due to economies of scale and competitive bidding.

FUTURE OUTLOOK AND MARKET TRENDS

The future supply landscape for eflornithine hydrochloride API will likely be shaped by evolving therapeutic needs, technological advancements, and ongoing regulatory scrutiny.

Continued Demand for Sleeping Sickness Treatment: Despite advancements in other neglected tropical disease control, African trypanosomiasis remains a public health concern in endemic regions. Continued global health initiatives will sustain demand for eflornithine hydrochloride.
Growth in Cosmetic Applications: The demand for topical eflornithine hydrochloride for hirsutism treatment is expected to grow, driven by increased consumer awareness and market penetration of cosmetic products. This could lead to increased investment in dedicated production lines by some manufacturers.
Focus on Supply Chain Resilience: Pharmaceutical companies will increasingly prioritize supply chain resilience. This will involve further investment in supplier diversification, dual sourcing strategies, and robust risk management frameworks.
Advancements in Manufacturing Technology: Continuous process improvement and the adoption of advanced manufacturing technologies could lead to more efficient and cost-effective production of eflornithine hydrochloride, potentially lowering API costs.
Regulatory Harmonization: Ongoing efforts in regulatory harmonization may simplify the qualification and approval process for API manufacturers across different markets, potentially opening doors for new entrants if manufacturing costs can be competitive.

KEY TAKEAWAYS

The global supply of eflornithine hydrochloride API is concentrated among a limited number of manufacturers, primarily in India and China, with a few European players.
Key suppliers include IPCA Laboratories, Divi’s Laboratories, Hubei Biocause Pharmaceutical, and AnkeBio.
Compliance with USP, Ph. Eur., ICH Q7 GMP, and potential WHO prequalification is critical for market access.
Supply chain risks include single-sourcing dependency, geopolitical factors, and lead times, necessitating diversification and robust quality agreements.
Pricing is influenced by COGS, regulatory costs, and market demand, with significant differentiation between humanitarian tenders and commercial markets.
Future trends point to sustained demand for therapeutic use, potential growth in cosmetic applications, and an intensified focus on supply chain resilience.

FREQUENTLY ASKED QUESTIONS

What are the primary regulatory bodies governing eflornithine hydrochloride API production? The primary regulatory bodies are the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national competent authorities, all guided by pharmacopoeial standards like USP and Ph. Eur., and ICH Q7 for GMP.
How does the WHO prequalification process impact eflornithine hydrochloride API suppliers? WHO prequalification is a rigorous assessment of API and finished product quality, safety, and efficacy. Suppliers seeking to provide eflornithine hydrochloride for WHO-administered sleeping sickness treatment programs must achieve this status.
What are the main differentiators among eflornithine hydrochloride API suppliers? Key differentiators include production capacity, established regulatory track record (FDA, EMA inspections), compliance with specific pharmacopoeial standards, pricing competitiveness, and reliability of supply.
Can pharmaceutical companies easily switch between eflornithine hydrochloride API suppliers? Switching suppliers is a complex process. It requires rigorous technical transfer, validation of analytical methods, potential re-validation of drug product manufacturing processes, and new regulatory filings or amendments, which can be time-consuming and costly.
What is the typical lead time for a large order of eflornithine hydrochloride API? Typical lead times for large orders of specialized APIs like eflornithine hydrochloride can range from 3 to 9 months, depending on the supplier's production schedule, current inventory, and the complexity of the manufacturing process.

CITATIONS

[1] IPCA Laboratories Ltd. (n.d.). API Business. Retrieved from https://www.ipca.com/api-business/ [2] Divi’s Laboratories Limited. (n.d.). API – Active Pharmaceutical Ingredients. Retrieved from https://www.divis.com/api [3] Laurus Labs Limited. (n.d.). API Manufacturing. Retrieved from https://www.lauruslabs.com/business-areas/api/ [4] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.biocause.com/en/products.html (Note: Specific eflornithine hydrochloride product information may require navigating the site or direct inquiry) [5] Chephapharma GmbH & Co. KG. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.chephapharma.com/en/capabilities/api-manufacturing/ [6] World Health Organization. (2022). Neglected tropical diseases progress report 2022. Retrieved from https://www.who.int/publications/i/item/9789240064786 [7] United States Pharmacopeial Convention. (n.d.). USP-NF. Retrieved from https://www.uspnf.com/ (Access to specific monographs requires subscription) [8] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-ph-eur- (Access to specific monographs requires subscription) [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide For Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/page/quality-guidelines [10] World Health Organization. (n.d.). Prequalification of Medicines Programme. Retrieved from https://www.who.int/teams/regulation-prequalification/medicines

Suppliers and packagers for generic pharmaceutical drug: EFLORNITHINE HYDROCHLORIDE